Contineum’s J&J-partnered MS drug fails to improve vision in phase 2
Contineum Therapeutics’ M1 receptor antagonist has failed to move the needle in a phase 2 vision test for patients with a common form of multiple sclerosis. The Johnson & Johnson-partnered…